《生物多样性公约》框架下合成生物学 谈判新进展及我国对策

doi:10.17520/biods.2015151

摘要/Abstract

摘要：

合成生物学技术和产品因其广阔的应用前景和难以预知的生态风险, 受到各国的广泛关注。2014年10月在韩国平昌召开的《生物多样性公约》第十二次缔约方大会上, 合成生物学首次被作为正式议题进行讨论。本文梳理了《生物多样性公约》框架下合成生物学从提出到成为“新的与正在出现的议题”的过程, 分析了《生物多样性公约》在该议题上对缔约国的最新要求, 以及我国合成生物学技术发展和风险评估现状。当前我国合成生物学研究处于起步阶段,近年来的科研投入不断增大,但距离成熟的商业化仍有相当距离。我国对相关技术风险评估能力欠缺,且尚未明确负责其生物安全管理的主管部门。本文提出了以严控风险、适度鼓励研究开发和要求发达国家提供更多技术支持的谈判对策, 以及明确合成生物学安全风险管理的政府主管部门、通过技术开发以推动风险评估、构建国家合成生物学数据库和建立专业风险评估团队等履约建议。

关键词: 生态安全, 新的与正在出现的议题, 履约对策, 公约谈判, 风险评估与管理

Abstract

Much attention has been paid to synthetic biology in recent years for its potential applications and unpredictable eco-risks. The 12th Conference of the Parties (COP12) of Convention on Biological Diversity (CBD), held in Korea in October 2014, formally addressed the topic of synthetic biology for the first time. Based on literature retrieved from CBD documents and technical reports, this paper reviews the process by which synthetic biology entered the agenda of CBD negotiations and provides the latest updates on this issue. Given the latest demands made and China’s current status in the development and risk assessment of synthetic biology, we analyze the challenges that China is facing in relation to negotiation and implementation. Research in synthetic biology in China is still in its early stages. Despite the surging investments in scientific research this field, wide application and commercialization is not to be expected in the near future. China's capacity to assess risks of associated technologies is rather limited and no government agency is explicitly in charge of bio-security in this respect yet. We propose that the Chinese delegation should argue for positions including strictly controlling risks, encouraging responsible development, and calling for more technical and technological support from developed countries during the negotiations of risk assessment. Further, we suggest that establishing accountability of the governing administrative department, promoting the development of risk assessment techniques, compiling a synthetic biology national database, and organizing professional risk-assessment teams are the key implementation strategies for CBD.

Key words: synthetic biology, eco-security, new and emerging issues, implementation strategy, international negotiations, risk assessment and management

邱明昊, 黄越, 张洁清, 黄艺 (2016) 《生物多样性公约》框架下合成生物学谈判新进展及我国对策. 生物多样性, 24, 114-120. DOI: 10.17520/biods.2015151.

Minghao Qiu, Yue Huang, Jieqing Zhang, Yi Huang (2016) International negotiations on synthetic biology and China’s implementation strategies within the Convention on Biological Diversity framework. Biodiversity Science, 24, 114-120. DOI: 10.17520/biods.2015151.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.biodiversity-science.net/CN/10.17520/biods.2015151

https://www.biodiversity-science.net/CN/Y2016/V24/I1/114

参考文献 31

1	Benner SA, Sismour AM (2005) Synthetic biology. Nature Reviews Genetics, 6, 533-543.
2	Breitling R, Takano E (2015) Synthetic biology advances for pharmaceutical production. Current Opinion in Biotechnology, 35, 46-51.
3	CBD (Convention on Biological Diversity) (2008) Decision Adopted by the Conference of the Parties to the Convention on Biological Diversity at its Ninth Meeting IX/29. https://www.cbd.int/doc/decisions/cop-09/cop-09-dec-29-en.pdf (accessed 2015-5-17)
4	CBD (Convention on Biological Diversity) (2014a) New and Emerging Issues: Synthetic Biology. https://www.cbd.int/doc/decisions/cop-12/cop-12-dec-24-en.pdf (accessed 2015- 5-17)
5	CBD (Convention on Biological Diversity) (2014b) Synthetic Biology: Updated Reports. https://www.cbd.int/doc/meet-ings/cop/cop-12/official/cop-12-20-en.pdf (accessed 2015-5- 17)
6	Chen GQ, Wang Y (2015) Progress in synthetic biology of “973 Funding Program” in China. Chinese Journal of Biotechnology, 31, 995-1008. (in Chinese with English abstract)
	[陈国强, 王颖 (2015) 中国“合成生物学”973项目研究进展. 生物工程学报, 31, 995-1008.]
7	Collins J (2012) Synthetic Biology: Bits and pieces come to life. Nature, 483, S8-S10.
8	Endy D (2005) Foundations for engineering biology. Nature, 438, 449-453.
9	EGE (European Group on Ethics in Science and New Technologies to the European Commission) (2009) Opinion No. 25: Ethics of Synthetic Biology.
10	Garfinkel MS, Endy D, Epstein GL, Friedman RM (2007) Synthetic Genomics: Options for Governance. Biosecurity & Bioterrorism Biodefense Strategy Practice & Science, 5, 359-361.
11	Gibson DG, Glass JI, Lartigue C, Noskov VN, Noskov RY, Algire MA, Algire GA, Montague MG, Ma L, Moodie MM, Moodie C, Vashee S, Krishnakumar R, Assad-Garcia N, Assad-Garcia C, Denisova EA, Young L, Qi ZQ, Segall-Shapiro TH, Calvey CH, Parmar PP, Hutchison III CA, Smith HO, Venter JC (2010) Creation of a bacterial cell controlled by a chemically synthesized genome. Science, 329, 52-56.
12	Guan ZJ, Pei L, Schmidt M, Wei W (2012) Assessment and management of biosafety in synthetic biology. Biodiversity Science, 20, 138-150. (in Chinese with English abstract)
	[关正君, 裴蕾, Markus Schmidt, 魏伟 (2012) 合成生物学生物安全风险评价与管理. 生物多样性, 20, 138-150.]
13	Kelle A (2009) Security issues related to synthetic biology between threat perceptions and governance options. In: Synthetic Biology: The Technoscience and Its Societal Consequences (eds Schmidt M, Kelle A, Ganguli A, de Vriend H), pp.101-119. Springer Academic Publishing, NewYork.
14	Kitney R, Freemont P (2012) Synthetic biology: the state of play. FEBS Letters, 15, 2029-2036.
15	Li J, Li SS, Wei Q, Wang ZJ (2013) Synthetic biology: biosafety and management strategy analysis. China Medical Equipment, 10(6), 68-71. (in Chinese with English abstract)
	[李晶, 李思思, 魏强, 王子军 (2013) 合成生物学的生物安全问题及对策分析. 中国医学装备, 10(6), 68-71.]
16	Liu D, Du J, Zhao GR, Yuan YJ (2011) Applications of synthetic biology in medicine and energy. Journal of Chemical Industry and Engineering, 62, 2391-2397. (in Chinese with English abstract)
	[刘夺, 杜瑾, 赵广荣, 元英进 (2011) 合成生物学在医药及能源领域的应用. 化工学报, 62, 2391-2397.]
17	Mackenzie R, Burhenne-Guilmin FLV, Antonio GM, Werksman JD (2003) An Explanatory Guide to the Cartagena Protocol on Biosafety. IUCN, Gland, Switzerland and Cambridge, UK.
18	Moe-Behrens GHG, Davis R, Haynes KA (2013) Preparing synthetic biology for the world. Frontiers in Microbiology, 4, 5.
19	PCSBI (Presidential Commission for the Study of Bioethical Issues) (2010) New Directions: The Ethics of Synthetic Biology and Emerging Technologies.
20	RAE (The Royal Academy of Engineering) (2009) Synthetic Biology: scope, applications and implications. The Royal Academy of Engineering, London.
21	SBSTTA (Subsidiary Body on Scientific, Technical and Technological Advice) (2010) New and Emerging Issues. https://www.cbd.int/doc/meetings/sbstta/sbstta-14/official/sbstta-14-18-en.pdf (accessed 2015-5-17)
22	Secretariat of the Convention on Biological Diversity (2000) Cartagena Protocol on Biosafety to the Convention on Biological Diversity: Text and Annexes.
23	Sleator RD (2014) The synthetic biology future. Bioengineered, 5, 69-72.
24	Sutherland W, Clout M, Cote I, Daszak P, Depledge M, Fellman L, Fleishman E, Garthwaite R, Gibbons D, De Lurio J, Impey A, Lickorish F, Lindenmayer D, Madgwick J, Margerison C, Maynard T, Peck L, Pretty J, Prior S, Redford K, Scharlemann J, Spalding M, Watkinson A (2010) A horizon scan of global conservation issues for 2010. Trends in Ecology and Evolution, 25, 1-7.
25	The International Civil Society Working Group on Synthetic Biology (2011) A Submission to the Convention on Biological Diversity’s Subsidiary Body on Scientific, Technical and Technological Advice (SBSTTA) on the Potential Impacts of Synthetic Biology on the Conservation and Sustainable Use of Biodiversity. https://www.cbd.int/doc/emerging-issues/Int-Civil-Soc-WG-Synthetic-Biology-2011- 013-en.pdf (accessed 2015-5-17)
26	UNICRI (United Nations Interregional Crime and Justice Research Institute) (2011) Security Implications of Synthetic Biology and Nanobiotechnology.
27	Vincent MJJ, Pitera DJ, Withers ST, Newman JD, Keasling JD (2003) Engineering a mevalonate pathway in Escherichia coli for production of terpenoids. Nature Biotechnology, 7, 796-802.
28	Wang HH, Isaacs FJ, Carr PA, Sun ZZ, Xu G, Forest CR, Church GM (2009) Letters: programming cells by multiplex genome engineering and accelerated evolution. Nature, 460, 894-899.
29	WTO (2006) European Communities—Measures Affecting the Approval and Marketing of Biotech Products. https://www.wto.org/english/tratop_e/dispu_e/cases_e/ds291_e.htm (accessed 2015-5-17)
30	Zhang LY, Chang SH, Wang J (2011) Synthetic biology: from the first synthetic cell to see its current situation and future development. Chinese Science Bulletin, 56, 229-237.
31	Zhu XH, Li Z (2011) The research progress and future applications of synthetic biology. Forum on Science and Technology in China, (5), 143-148. (in Chinese with English abstract)
	[朱星华, 李哲 (2011), 合成生物学的研究进展与应用. 中国科技论坛, (5), 143-148.]

[1]	张琨, 邹长新, 张怡, 刘晓曼, 高吉喜. 从划定历程与属性特征正确认识生态保护红线内涵[J]. 生物多样性, 2022, 30(4): 21464-.
[2]	莫张勤. 生态保护红线修复机制法治化: 定位、困境及其出路[J]. 生物多样性, 2019, 27(3): 347-352.
[3]	Richard Corlett. 生物多样性和生态系统服务：实现东亚热带和亚热带的生态安全[J]. 生物多样性, 2018, 26(7): 766-774.
[4]	张殷波, 傅靖轩, 刘莹立, 白帆, 桑卫国. 我国珍稀濒危植物保护红线的划定[J]. 生物多样性, 2015, 23(6): 733-739.
[5]	徐德琳, 邹长新, 徐梦佳, 游广永, 吴丹. 基于生态保护红线的生态安全格局构建[J]. 生物多样性, 2015, 23(6): 740-746.
[6]	刘冬, 林乃峰, 邹长新, 游广永. 国外生态保护地体系对我国生态保护红线划定与管理的启示[J]. 生物多样性, 2015, 23(6): 708-715.
[7]	卢宝荣, 夏辉, 汪魏, 杨箫. 天然杂交与遗传渐渗对植物入侵性的影响[J]. 生物多样性, 2010, 18(6): 577-589.
[8]	郭中伟, 甘雅玲. 关于生态系统服务功能的几个科学问题[J]. 生物多样性, 2003, 11(1): 63-69.
[9]	万方浩, 郭建英, 王德辉. 中国外来入侵生物的危害与管理对策[J]. 生物多样性, 2002, 10(1): 119-125.